FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 319 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 NCI Expands Repository of Cancer Research Models: A Conversation with Drs.... April 20, 2018 Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... March 22, 2023 Νέα για τον καρκίνο του προστάτη June 9, 2019 Load more HOT NEWS More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia
